Nanoparticles may be solution against antibiotic resistance

Image
IANS London
Last Updated : Dec 16 2017 | 12:15 PM IST

Scientists have succeeded in developing an effective method to treat the often lethal airway infections with nanoparticles that transport the antibiotics more efficiently to their destination.

Mucoviscidosis, also known as cystic fibrosis, is an inherited life-threatening disorder that damages the lungs and digestive system.

The lung is so significantly damaged that patients often die or need to have a lung transplant. Permanent treatment with inhaled antibiotics play a considerable part in this.

While, the treatment can not avoid the colonisation by bacteria completely but it can keep it in check for a longer period of time.

The bacteria defends themselves with a development of resistance, but with the growth of so-called biofilms underneath the layer of mucus, which mostly block off the bacteria in the lower rows like a protective shield.

"Typically, the drugs are applied by inhalation in the body. Then they make a complicated way through the body to the pathogens and many of them don't make it to their destination," Dagmar Fischer, Chair for Pharmaceutical Technology at the University of Jena, in Germany, said in a statement.

To overcome the strong defense, the researchers encapsulated the active agents, like the antibiotic Tobramycin, in a polyester polymer.

Thus, they created a nanoparticle which they then tested in the laboratory where they beforehand had simulated the present lung situation, in a static as well as in a dynamic state, i.e. with simulated flow movements.

The scientists discovered that their nanoparticle travels more easily through the sponge-like net of the mucus layer and is finally able to kill off the pathogens without any problems.

Moreover, an additionally applied coating of polyethylenglycol makes it nearly invisible for the immune system.

"All materials of a nanocarrier are biocompatible, biodegradable, nontoxic and therefore not dangerous for humans," the researchers noted.

--IANS

rt/ksk

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 16 2017 | 12:10 PM IST

Next Story